0001562180-24-003337.txt : 20240405 0001562180-24-003337.hdr.sgml : 20240405 20240405202133 ACCESSION NUMBER: 0001562180-24-003337 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240405 FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CHILDS JOHN W CENTRAL INDEX KEY: 0001027035 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41477 FILM NUMBER: 24827871 MAIL ADDRESS: STREET 1: 111 HUNTINGTON AVENUE STREET 2: SUITE 2900 CITY: BOSTON STATE: MA ZIP: 02199 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Ltd. CENTRAL INDEX KEY: 0001935979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 FORMER COMPANY: FORMER CONFORMED NAME: Biohaven Research Ltd. DATE OF NAME CHANGE: 20220629 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-04-05 false 0001935979 Biohaven Ltd. BHVN 0001027035 CHILDS JOHN W C/O BIOHAVEN LTD. 215 CHURCH STREET NEW HAVEN CT 06510 true false false false false Common Shares 2024-04-05 4 A false 2091.00 A 2181671.00 I By John W Childs 2013 Revocable Trust Pursuant to a merger transaction, consummated on January 8, 2024, 48,505 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 2,091 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. /s/ George Clark, Attorney-in-Fact 2024-04-05